SEC Tracker
Get the app

Lite Strategy LITS

Lite Strategy reports $16.02 million net income for fiscal Q1 2027

Form
10-Q
Filed
Importance
Notable
  1. Net income: $16.02 million for the three months ended Sep 30, 2026
  2. Diluted EPS: $0.48 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $4.28 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Lite Strategy files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

  • For the quarter ended September 30, 2026, Lite Strategy, Inc. reported: Net income $16.0 million.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Actinium Pharmaceuticals ATNM public float $44M, Jun 30, 2025
  2. Fortress Biotech FBIO public float $44M, Jun 30, 2025
  3. Actuate Therapeutics ACTU public float $42M, Jun 30, 2025
  4. Acumen Pharmaceuticals ABOS public float $45M, Jun 30, 2025
  5. Opus Genetics IRD public float $46M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.